Literature DB >> 23855303

Interaction of hepatic stellate cells with diverse types of immune cells: foe or friend?

Hyon-Seung Yi1, Won-Il Jeong.   

Abstract

Activated hepatic stellate cells (HSCs) have been considered as a major type of cells in liver fibrosis by producing a huge amount of extracellular matrix, especially collagen fibers, and profibrotic mediators such as transforming growth factor-beta, interleukin-6 and monocyte chemoattractant protein-1. Recently, accumulated evidence suggests that the liver is an immunologic organ because of enrichment of diverse types of immune cells and that their interactions with HSCs are closely related with the progression of liver fibrosis. However, the underlying mechanisms of interaction between HSCs and immune cells remain largely unknown. Recently, several studies have demonstrated that natural killer cells, M2 macrophages, regulatory T cells, and bone marrow derived CD11b(+) Gr1(+) immature cells ameliorate liver fibrosis, whereas neutrophils, M1 macrophages, CD8 T cells, natural killer T cells and interleukin-17-producing cells accelerate liver fibrosis. However, there are still controversial issues about their functions during liver fibrogenesis. In this review, we summarize the diversity roles of immune cells (e.g. profibrotic/antifibrotic or both) in regulating the activation of HSCs during hepatic fibrogenesis, in which several producible mediators by HSCs play important roles in the interaction with them. Moreover, the current cell-based therapies using immune cells against liver fibrosis are discussed.
© 2013 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  bone marrow cell; interleukin-17; macrophage; natural killer cell; regulatory T cell

Mesh:

Substances:

Year:  2013        PMID: 23855303     DOI: 10.1111/jgh.12017

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  26 in total

Review 1.  Hepatic non-parenchymal cells: Master regulators of alcoholic liver disease?

Authors:  Wonhyo Seo; Won-Il Jeong
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

2.  Nutrigenomics analysis reveals that copper deficiency and dietary sucrose up-regulate inflammation, fibrosis and lipogenic pathways in a mature rat model of nonalcoholic fatty liver disease.

Authors:  Savannah Tallino; Megan Duffy; Martina Ralle; María Paz Cortés; Mauricio Latorre; Jason L Burkhead
Journal:  J Nutr Biochem       Date:  2015-05-15       Impact factor: 6.048

3.  Sparstolonin B (SsnB) attenuates liver fibrosis via a parallel conjugate pathway involving P53-P21 axis, TGF-beta signaling and focal adhesion that is TLR4 dependent.

Authors:  Diptadip Dattaroy; Ratanesh Kumar Seth; Sutapa Sarkar; Diana Kimono; Muayad Albadrani; Varun Chandrashekaran; Firas Al Hasson; Udai P Singh; Daping Fan; Mitzi Nagarkatti; Prakash Nagarkatti; Anna Mae Diehl; Saurabh Chatterjee
Journal:  Eur J Pharmacol       Date:  2018-09-05       Impact factor: 4.432

4.  Impaired balance of T helper 17/T regulatory cells in carbon tetrachloride-induced liver fibrosis in mice.

Authors:  Xiao-Fei Sun; Lei Gu; Wen-Sheng Deng; Qing Xu
Journal:  World J Gastroenterol       Date:  2014-02-28       Impact factor: 5.742

5.  Activated pancreatic stellate cells inhibit NK cell function in the human pancreatic cancer microenvironment.

Authors:  Qiang Huang; Mei Huang; Futao Meng; Rui Sun
Journal:  Cell Mol Immunol       Date:  2018-04-08       Impact factor: 11.530

Review 6.  Non-alcoholic fatty liver disease: what the clinician needs to know.

Authors:  Mariana Verdelho Machado; Helena Cortez-Pinto
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

Review 7.  IL-17 Axis Driven Inflammation in Non-Alcoholic Fatty Liver Disease Progression.

Authors:  Daniel A Giles; Maria E Moreno-Fernandez; Senad Divanovic
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

Review 8.  Alcoholic liver disease: a new insight into the pathogenesis of liver disease.

Authors:  Seol Hee Park; Young-Sun Lee; Jaemin Sim; Seonkyung Seo; Wonhyo Seo
Journal:  Arch Pharm Res       Date:  2022-06-27       Impact factor: 6.010

Review 9.  Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update.

Authors:  Gülsüm Özlem Elpek
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

Review 10.  Immune dysfunction in cirrhosis.

Authors:  Nora Sipeki; Peter Antal-Szalmas; Peter L Lakatos; Maria Papp
Journal:  World J Gastroenterol       Date:  2014-03-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.